We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Abbott, Teva Settle Patent Dispute Over TriCor, But Antitrust Claims Remain

Law360 (June 9, 2005, 12:00 AM EDT) -- Abbott Laboratories has settled a patent dispute with Israeli drug maker Teva Pharmaceutical Industries Ltd. over a generic version of Abbott's best-selling cholesterol treatment TriCor.

Abbott said the litigation had been amicably resolved and the parties have agreed to dismiss the patent claims, allowing Teva to go ahead with the launch of a generic TriCor.

However, Abbott said Teva's generic drug would be the equivalent of Abbott's older formulation of TriCor, not the newer formulation that Abbott has been marketing since getting Food and Drug Administration...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.